<?xml version="1.0" encoding="UTF-8"?>
<p>The most clinically relevant symptom related to CHIKV infection is peripheral symmetrical joint pain (primarily inflammatory polyarthralgia). Manifested in several CHIKV cases, it can lead to significant economic impacts and severely affect the patient’s quality of life [
 <xref rid="ppat.1007880.ref012" ref-type="bibr">12</xref>]. The pain starts in the acute phase and can persist for years in up to 50% of the infected adult individuals [
 <xref rid="ppat.1007880.ref051" ref-type="bibr">51</xref>]. Notably, it was proposed that CHIKV infection produced autoimmune sequelae [
 <xref rid="ppat.1007880.ref052" ref-type="bibr">52</xref>]. Although polyarthralgia is rarely detected (5–11%) in children, other kinds of severe manifestations can occur [
 <xref rid="ppat.1007880.ref053" ref-type="bibr">53</xref>]. Since there are neither effective treatments nor licensed vaccines against CHIKV infection, understanding the molecular mechanisms of this complex infection is essential for the development of effective therapies and even vaccines.
</p>
